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bhis review focuses on published works in 2005, up to April
006, that have implications for clinical practice in the
linical management of hypertension. It has been an event-
ul year with a number of key publications. We have gained
ew insights into the epidemiology of hypertension and
etter characterization of the “hypertensive phenotype” that
oses challenging questions about when and how to begin
reatment in people at risk of developing hypertension. We
ave also begun to gain a better understanding of the clinical
ignificance of atrial fibrillation in people with hypertension
nd of the treatment strategies for its prevention. Further
tudies have yielded important new information about the
ifferential impact of blood pressure (BP)-lowering drugs on
entral aortic pressure and its potential role in clinical
utcomes. These studies have complemented new data from
ajor clinical outcomes trials that have served to consolidate
he evidence base for some aspects of existing hypertension
reatment guidance but also have questioned the role of
eta-blockade as a routine treatment for hypertension. This
as been an invigorating year of discovery that has begun to
hift the foundations that have previously provided a stable
latform for current thinking. There seems little doubt that
hese new data will be the catalyst for new ideas and
ltimately a reappraisal and revision of hypertension treat-
ent guidelines in the year to come.
HE GLOBAL BURDEN OF HYPERTENSION
ecently, the global prevalence of hypertension (defined as
n average systolic BP of 140 mm Hg or greater, a diastolic
P of 90 mm Hg or greater, or the use of antihypertensive
edication) was estimated for the year 2000 and the data
sed to predict the global prevalence of hypertension by
025 (Fig. 1) (1). More than 25% of the world’s adult
opulation was hypertensive by the aforementioned criteria
n 2000. The estimated total number of people with
ypertension in 2000 was 972 million, and this is projected
o increase by 60% to a total of 1.56 billion by 2025, that is,
9% of the worldwide adult population. Most of this
ncrease is expected to result from an increase in the number
f people with hypertension in economically developing
egions, so that almost 75% of the world’s hypertensive
opulation will reside in economically developing countries
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Manuscript received June 20, 2006; accepted June 28, 2006.y 2025. Although hypertension is more common in eco-
omically developed countries (37.3%) than in those classi-
ed as undergoing economic development (22.9%), hyper-
ension is a greater population burden in economically
eveloping countries because of their much larger popula-
ions.
These projections for 2025 are based on the assumption
hat the country, age, and gender-specific prevalence esti-
ates remain constant and are likely to be conservative,
indful of the rapidly changing lifestyles, and in particular
he increasing prevalence of obesity and sedentary lifestyles
n these regions, which increases the risk of developing
ypertension. Overall, the prevalence of hypertension in all
egions increases with age, more steeply in women. By the
ge of 60, more than half of adults in most regions of the
orld will be hypertensive, with the lowest current and
rojected rates in India and Asia and the highest rates in
atin America and the Caribbean, former Socialist Repub-
ics, and sub-Saharan Africa. These alarming figures high-
ight that high BP is set to remain the single most important
reventable cause of premature death worldwide over the
ext 2 decades.
YPERTENSION AWARENESS,
ETECTION, AND CONTROL
ata on control rates for hypertension are periodically
eleased worldwide, and the data for the U.S. were recently
eviewed (2). The U.S. NHANES (National Health and
utrition Examination Survey) studies have revealed a
teady increase in awareness of hypertension (70%), up to
000, an increase in treatment rates (55%) but less
rogress in the percentage of those with hypertension whose
P is controlled to recommended goals on treatment, which
ontinues to hover around 25% (Fig. 2). It should be noted,
owever, that the criteria for control have been tightened
rom 160/95 mm Hg in the earlier NHANES surveys to
140/90 mm Hg in the most recent. The Healthy People
010 report (3) targets a control rate for the U.S. population
f 50% in 5 years, which would only be reached if at least
0% of people with hypertension were aware of their
ondition, 90% were treated, and 70% of those treated had
heir condition controlled (4)—there is still much work to
e done if these laudable aspirations are to be realized.
The reasons for the slow progress on BP control rates are
any and have been recently comprehensively reviewed (2),
ut perhaps an important and less commonly appreciated
eason is that the earliest indicators of the “hypertensive
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October 17, 2006:1698–711 The Year in Hypertensionhenotype” are overlooked until hypertension is well estab-
ished and thus more resistant to treatment. This concept
as been reinforced by the data discussed later.
HE HYPERTENSIVE PHENOTYPE
t has been suggested that the cumulative lifetime risk of
eveloping hypertension approaches 90% in a Western
igure 1. Frequency of hypertension in people ages 20 years and older by
anel). Reprinted with permission from Kearney et al. (1).
igure 2. Trends in awareness, treatment, and control of hypertension in
he U.S., 1960 to 2000. Definition of blood pressure control is 160/95
m Hg for NHES (National Health Examination Survey), NHANES
National Health and Nutrition Examination Survey) I, and NHANES IIf
nd 140/90 mm Hg for NHANES III and NHANES 1999 to 2000.
eprinted with permission from Wang et al. (2).opulation (5), a trend that is likely to follow in developing
ountries without lifestyle modification. This observation
rompts 2 questions: 1) is there a hypertensive phenotype
hat could be identified early? 2) If there is such a pheno-
ype, would early intervention in the “prehypertension”
hase lead to the prevention of hypertension, or at least
educe the risk of developing more severe/resistant hyper-
ension, and thereby help challenge the stubbornly poor
ontrol rates of more established hypertension? These are
ey questions that have begun to be addressed by studies in
he past year.
The risk factors for developing hypertension in adults
ere recently evaluated from the Strong Heart Study, a
opulation-based longitudinal cohort study of cardiovascu-
ar risk factors in Native Americans from 3 communities in
rizona (6). Unsurprisingly, initial BP was a strong predic-
or of incident hypertension. However, incident hyperten-
ion could also be predicted by a person’s initial metabolic
rofile and unfavorable metabolic variations over time. Even
n those with optimal initial BP levels (120/80 mm Hg),
ncreasing abdominal obesity and abnormal lipid profile
ere major predictors of the development of hypertension.
he participants were examined at baseline, at 4 years, and
t 8 years. In those with a normal baseline glucose tolerance,
s well as an optimal BP, higher baseline waist circumfer-
nce and systolic BP, as well as evidence of diabetes at 4
ears, increases in systolic BP and waist circumference, and
decrease in high-density lipoprotein (HDL) cholesterol
region and gender in 2000 (upper panel) and projected to 2025 (lowerrom baseline to the second examination predicted hyper-
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The Year in Hypertension October 17, 2006:1698–711ension at 8 years. It was also of interest that the 4-year
ecrease in HDL cholesterol was as strong an independent
redictor of 8-year incident hypertension as the baseline
evel of systolic BP. Similarly, a recent report examining
actors predicting development of hypertension from the
hysicians’ Health Study also reported a powerful associa-
ion between disturbed lipid metabolism and the risk of
eveloping hypertension (7). After following up this cohort
or a mean of 14 years, using Cox proportional hazards
odeling adjusted for lifestyle and clinical risk factors, men
n the highest quintile of total cholesterol, non-HDL
holesterol, and the ratio of total to HDL cholesterol had
ncreased risks of developing hypertension of 23%, 39%, and
4%, respectively, compared with participants in the lowest
uintile. Moreover, men in the highest quintile of HDL
holesterol had a 32% decreased risk of developing hyper-
ension compared with those in the lowest quintile.
Together, these observations support previous reports
haracterizing the prehypertensive phenotype (8–10) and
ighlight that this phenotype is a complex mix of dysregu-
ated BP and metabolism that is potentially amenable to
arly lifestyle and/or drug interventions designed to prevent
he development of hypertension.
he TROPHY study. With regard to early intervention
imed at preventing the development of hypertension, the
ROPHY (Trial of Preventing Hypertension) study has
igure 3. TROPHY (Trial of Preventing Hypertension) study design (u
ypertension. Reprinted with permission from Julius et al. (11).rovided some important insights (11). A total of 809 weople with “prehypertension” (systolic BP 130 to 139 mm
g; diastolic BP 89 mm Hg or lower) were all offered
ifestyle advice for the duration of the study and randomized
o treatment with either an angiotensin receptor blocker
ARB) (candesartan 16 mg once daily) or placebo for the
rst 2 years of follow-up, then placebo for both groups for
further 2 years of follow-up (Fig. 3). The objective was to
etermine whether drug treatment of prehypertension pre-
ented or postponed the development of stage 1 hyperten-
ion. During the first 2 years, hypertension developed in 154
articipants in the placebo group and in 53 of those in the
andesartan group, a relative risk reduction of 66.3% (p 
.001). The active treatment was then stopped and con-
erted to placebo for a further 2 years. Thus, after a total
ollow-up of 4 years, hypertension had developed in 240
articipants in the placebo group and 208 of those originally
ssigned to the candesartan group, a relative risk reduction
f 15.6% (p  0.007).
The TROPHY study highlights some key points: 1)
ifestyle intervention alone, as offered in the study, was
isappointing at preventing the development of hyperten-
ion because stage 1 hypertension had developed in almost
/3 of the patients in the placebo group after 4 years. 2) The
ransition rate from prehypertension to established hyper-
ension was alarmingly high. 3) Early pharmacologic treat-
ent markedly retarded the elevation of BP, but this benefit
panel) and Kaplan-Meier analysis (lower panel) of new-onset clinicalas lost after treatment was discontinued. 4) Continuation
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October 17, 2006:1698–711 The Year in Hypertensionf treatment would be required to maintain the retarded
ransition to stage 1 hypertension. It is tempting to specu-
ate that had pharmacologic treatment continued long-term,
his might have maintained a normal BP, thereby prevent-
ng progression to the well-recognized state identified by
he surveys discussed earlier of poorer BP control resistant
o treatment with multiple drug therapy.
It will be interesting to discover from subsequent
nalyses of the TROPHY data whether the pharmaco-
ogic treatment of the prehypertensive state also impacted
n the metabolic disturbances mentioned earlier, or more
ntriguingly, looking to future studies, whether treat-
ents targeting the metabolic disturbances per se that
haracterize the hypertensive phenotype might actually
revent the development of hypertension. The impor-
ance of the TROPHY study was not in the result, which
as largely predictable, but that it served to highlight the
otential of therapeutic strategies aimed at targeting the
arly hypertensive phenotype to prevent the development
f more severe hypertension.
IFESTYLE INTERVENTIONS
OR PEOPLE WITH HYPERTENSION
aving just reflected on how ineffective the lifestyle instruc-
ion offered in the TROPHY study was at preventing the
evelopment of hypertension, it may seem an inopportune
oment to reflect on recent data with regard to lifestyle
ntervention for hypertension. It is important to note,
owever, that much of the predicted increase in the global
revalence of hypertension will have its origins in poor
ifestyle choices, and that concerted efforts to adopt and
einforce the importance of healthier lifestyles remain the
oundation for tackling the emerging global epidemic of
ypertension and cardiovascular disease. In the past year, a
etailed meta-analysis quantifying the impact of various
ifestyle interventions on BP was reported (12). The Amer-
can Heart Association has also issued an updated scientific
tatement on the role of dietary interventions to both
revent and treat hypertension (13), and this notes some
mportant principles that are consistent with the findings of
he meta-analysis and are worthy of reiteration: 1) Well-
stablished dietary modifications that lower BP are reduced
alt intake, weight loss, and moderation of alcohol con-
umption. 2) Black subjects are especially sensitive to the
P-lowering effects of a reduced salt intake and the DASH
iet. 3) In those hypertensive patients already on drug
herapy, lifestyle modifications should continue, particularly
reduced salt intake, because this can add to the BP-
owering effect of drug therapy.
However, in light of the high transition rates from
rehypertension to stage I hypertension and beyond, in my
iew, it is questionable whether lifestyle intervention alone
ill continue to be regarded as sufficient for people with
ncomplicated stage 1 hypertension. AMBULATORY BP MEASUREMENT
here has been continuing debate about the relative merits
f various methods for measurement of BP. A key question
as been whether techniques such as ambulatory BP mea-
urement (ABPM) offer anything more in terms of predict-
ng mortality than conventional clinic BP measurements.
his was addressed in 2005 by the Dublin Outcome Study
14). This was a prospective study of 5,292 untreated
ypertensive patients referred to a single BP clinic. All
atients had clinic BP and ABPM at baseline. There were
46 deaths (of which 389 were cardiovascular). This large
umber of deaths allowed this study to evaluate the prog-
ostic significance of ABPM with regard to mortality for
he first time.
After adjustment for gender, age, risk indices, and clinic
P, higher mean values of ambulatory BP were independent
redictors for cardiovascular mortality. After correction for
ther risk factors, ambulatory BP was superior to clinic BP
or prediction of cardiovascular mortality. Moreover, night-
ime BP was the most potent predictor of outcome (Fig. 4).
his finding is consistent with another recent report from
apan that examined the relationship between ABPM and
atterns of stroke. In 1,430 people followed up for an
verage of 10 years, cerebral infarction risk was significantly
igher in “non-dippers” (i.e., people with a10% decline in
ight-time BP). On the other hand, an increased risk of
erebral hemorrhage was observed in people with a large
orning pressor surge (i.e., 25 mm Hg in the 2 h after
aking) (15).
These findings add to a growing body of evidence
howing that ambulatory BP per se and the diurnal charac-
eristics of BP are stronger predictors of clinical outcomes
han clinic BP. Furthermore, the observation that nighttime
P control is the strongest predictor of clinical outcome
uggests that treatment strategies that deliver 24-h BP
ontrol are likely to be important.
So, when to use ABPM? The routine use for all patients
s perhaps a step too far at this time, but ABPM is useful in
he assessment of the untreated patient when there is
ncertainty about the decision to treat and for assessing the
uality of BP control in patients at high risk. Moreover,
here needs to be greater use of ABPM and other strategies
o record BP in clinical outcome trials to better characterize
he effect of drugs on BP (16).
mbulatory arterial stiffness index (AASI). In an en-
eavor to further refine risk stratification using ABPM, the
ata have been used to derive an AASI. The physiological
rinciples underpinning the derivation of the AASI are that
rterial stiffness varies nonlinearly with distending pressure
hroughout the day and that the relationship between
ystolic and diastolic BP will depend on the functional
haracteristics of large conduit arteries—in people with
tiffer arteries, there will be a greater increase in systolic
ersus diastolic BP. It has therefore been proposed that the
ASI is a surrogate measure of arterial stiffness. Using all of
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The Year in Hypertension October 17, 2006:1698–711he readings from a 24-h ABPM recording, the AASI is
erived by plotting diastolic versus systolic BP and the
egression slope for this relationship is calculated. The
ASI has been defined as 1  this regression slope (17). In
upport of the concept that the AASI is a surrogate for
rterial stiffness, the AASI correlates with the pulse wave
elocity and pulse wave augmentation index and correlates
ore with the augmentation index than 24-h pulse pressure
17).
The use of AASI as a prognostic indicator of total and
ause-specific cardiovascular mortality was evaluated utiliz-
ng the Dublin Outcomes Study cohort described earlier.
aseline AASI was derived from ABPM recordings from
1,291 patients (mean age 54.6 years). Over a median
ollow-up of 5.3 years, before and after adjustment for other
ardiovascular risk factors, the AASI and pulse pressure
ignificantly predicted total cardiovascular mortality.
The AASI was a stronger predictor than pulse pressure
or stroke. The AASI seemed to be a stronger predictor of
troke mortality than pulse pressure, especially in normo-
ensive patients (18). Clearly, further physiological and
linical studies will be required to validate this novel risk
ndex and to confirm the predictive value of the AASI over
nd above conventional risk stratification in other cohorts. If
onfirmed and validated, the AASI could be readily com-
uted from standard ABPM recordings and may in future
rovide additional data for risk stratification. However, it is
nfortunate that the term AASI was applied to this index.
here is much misuse of the term arterial stiffness, as
xpertly reviewed in the accompanying editorial (19). The
oncept that the AASI is a measure of arterial stiffness is
implistic, and truer markers of arterial stiffness, such as
ulse wave velocity, have a stronger predictive value for
ortality than reported for the AASI (20). Perhaps a better
nd suitably vague term would have been an ambulatory
igure 4. Adjusted 5-year risk of cardiovascular death in the study cohort
sing multiple Cox regression, the relative risk was calculated with adju
ellitus, history of cardiovascular events, and smoking status. The 5-year ris
rom Dolan et al. (14).ascular index. cRIALS OF BP-LOWERING THERAPY
SCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
he BP-lowering arm of ASCOT (ASCOT-BPLA) was
ecently reported (21). The ASCOT was a multicenter
rospective randomized controlled trial of 19,257 people
ith hypertension, and had a mean age of 63 years. The
tudy had a factorial design that addressed 2 questions. The
rst question was whether the addition of a statin (atorva-
tatin 10 mg daily) would be more effective at reducing
ardiovascular events than placebo in a cohort of ASCOT
atients who would not otherwise have been treated with a
tatin. The results of the ASCOT lipid-lowering arm
ASCOT-LLA) were published in 2003 and clearly showed
hat the addition of a statin significantly reduced the risk of
oronary heart disease by 36% and stroke by 27% when
ompared with placebo (22). The benefits of statin therapy
ere recently reported to be similar in the cohort of patients
ith hypertension and diabetes at baseline (23).
The second question addressed by ASCOT-BPLA was
hether conventional BP-lowering therapy (atenolol 
endroflumethiazide-K, as required) was sufficient for op-
imal cardiovascular disease prevention when compared
ith a more contemporary regimen of newer drugs (amlo-
ipine  perindopril, as required). The patients were
redominantly male (77%), with a mean age of 63 years.
mportantly, people with a prior history of myocardial
nfarction or treated angina were excluded; thus, this was a
rimary prevention trial. The ASCOT-BPLA was stopped
arlier than anticipated (follow-up median 5.5 years) on the
ecommendation of the data safety monitoring board be-
ause of a clear benefit of the amlodipine-based therapy on
ost cardiovascular end points and total mortality (reduced
y 11%) and in particular on cardiovascular mortality
reduced by 24%), even though the primary end point (fatal
92 patients for clinic blood pressure (BP) and ambulatory BP monitoring.
t for baseline characteristics including gender, age, presence of diabetes
expressed as number of deaths per 100 people. Reprinted with permissionof 5,2
stmenoronary heart disease or nonfatal myocardial infarction)
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October 17, 2006:1698–711 The Year in Hypertensionas nonsignificantly different at the time the study was
erminated (21).
Some have argued that because most of the power of a
linical trial is invested in its primary end point, if this is not
ignificantly different, then subsequent analysis of secondary
nd points should be viewed with caution. This seems
nreasonable when a study is terminated because of safety
oncerns due to substantial and significant differences in key
nd points in favor of one of the treatment strategies. In
SCOT, when compared with atenolol-based treatment,
mlodipine-based treatment significantly reduced stroke by
3%, all-cause death by 11%, cardiovascular death by 24%,
nd all cardiovascular events and procedures by 16%. There
as also a significant 30% reduction in new-onset diabetes
n favor of amlodipine-based therapy (21).
The BP control was better throughout ASCOT-BPLA
ith amlodipine-based therapy, especially in the first few
onths. Moreover, the differences persisted, albeit to a
esser extent throughout the trial, despite greater use of
dd-on therapy with the atenolol-based therapy. These
ifferences in brachial BP between the treatment arms are
ikely to have been an important driver of the differences in
linical outcomes in ASCOT, but further analyses adjusting
or BP and other variables throughout the study suggested
hat other factors were also important (24). The CAFE
Conduit Artery Function Evaluation) study (25,26), a
ubstudy of ASCOT, suggested that the differential effects
f BP-lowering therapy on central aortic pressures may also
ave been an important determinant of the beneficial effect
f amlodipine-based therapy in ASCOT. This is further
iscussed later.
The ASCOT study confirmed the importance of initial
rug selection in defining the subsequent quality of BP
ontrol. The ASCOT study also showed that those patients
andomized to the most effective BP-lowering regimen
amlodipine-based therapy) and a statin had their risk of
troke and myocardial infarction reduced by half when
ompared with those randomized to conventional BP-
owering therapy without a statin. This is a very important
essage that reinforces a shift in thinking regarding the
ptimal management of risk in people with hypertension.
he cardiovascular disease risk of the typical ASCOT
atient was20% over 10 years, thereby suggesting that the
ypical hypertensive (i.e., European or American men over
0 years old) would have sufficient cardiovascular disease
isk to benefit from statin therapy, even if their cholesterol
evels appear normal. This is a very significant development
hat is already impacting treatment guidelines (27).
Finally, ASCOT also reinforced data from previous
tudies suggesting that beta-blocker–based therapy, espe-
ially in older patients (i.e., 55 years) is less effective than
lternative classes of therapy at reducing cardiovascular
vents, notably stroke, and is more likely, especially in
ombination with thiazide diuretics, to increase the risk of
eveloping diabetes. The impact of these findings on the pate of beta-blockers for the routine treatment of hyperten-
ion is discussed later.
he CAFE study. The CAFE study was a large substudy
f ASCOT that examined the hypothesis that the different
P-lowering drug regimens used in ASCOT could have
ad different effects on central aortic pressures despite
imilar effects on brachial BP (25,26). The CAFE study
ecruited 2,199 patients, and radial artery applanation
onometry and pulse wave analysis were used to derive
entral aortic pressures and hemodynamic indices. Despite a
imilar brachial systolic BP between treatment groups, there
ere significantly greater reductions in central aortic systolic
nd pulse pressures with the amlodipine-based treatment
egimen when compared with the atenolol-based regimen
Fig. 5). Thus, BP-lowering drugs have the potential to
ifferentially impact on central aortic pressures, despite
imilar effects on brachial BP. This important finding
uggests that brachial BP does not always faithfully reflect
he impact of different BP-lowering drugs on central aortic
ressures and hemodynamics. A similar conclusion has been
eached recently by other investigators using different drug
reatments in much smaller, shorter-term studies (28,29).
The CAFE study showed that the more effective central
ortic pressure lowering with the amlodipine-based therapy
esulted from reduced pulse wave reflection, pointing to the
mportance of vasodilatation as an important mechanism for
ptimizing the reduction in central aortic pressures.
hether the same differential drug effects on central pres-
ure would also have been observed in younger patients with
ore compliant arteries is unknown. Moreover, whether the
esult would have occurred with the newer generation of
asodilating beta-blockers is also unknown.
Using Cox proportional hazards modeling, the CAFE
nvestigators went on to show that on-treatment central
ulse pressure was significantly associated with clinical
utcomes (26). These findings suggest that differential drug
ffects on central aortic pressures could be an important
eterminant of drug-related differences in clinical outcomes
n clinical trials such as ASCOT and others that have often
eferred to drug benefits as “beyond blood pressure.” The
AFE findings also suggest that drug development pro-
rams that are predicated on regulatory requirements for
ffective reductions in brachial pressure may be underesti-
ating the potential benefit of drugs that favorably impact
ulse wave reflection.
In another study, baseline pulse wave analysis was per-
ormed in small a subset of participants in the ANBP-2
Australian National Blood Pressure Study 2) study to
erive central aortic pressures (30). In this analysis, there
ere only 53 events (in contrast to CAFE’s 305 events)
uring a median of 4.1 years of follow-up in 484 women.
he ANBP-2 study did not show that higher baseline
entral aortic pressures were a significant predictor of
linical outcomes. However, the study was clearly under-
owered to test this hypothesis and thus prone to a type 2
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The Year in Hypertension October 17, 2006:1698–711tatistical error, and differs from the CAFE study in that it
id not examine on-treatment pressures.
urther analyses from ALLHAT. The ALLHAT (Anti-
ypertensive and Lipid-Lowering Treatment to Prevent
eart Attack Trial) investigators continue to generate
mportant data from various subanalyses. The ALLHAT
ompared treatment with amlodipine or lisinopril with the
eference drug chlorthalidone. The primary end point was
atal coronary heart disease or nonfatal myocardial infarc-
ion. Three reports have emerged in the past year looking at
linical outcomes from prespecified subgroup analyses: 1)
lack and nonblack patients (31), 2) people with diabetes
32), and 3) renal outcomes (33).
LLHAT outcomes in black and nonblack patients.
his was an important prespecified analysis because of the
aucity of clinical outcome data in variety of ethnic groups
ith hypertension. In ALLHAT, 11,792 patients were
igure 5. Brachial (solid symbols) and derived central aortic (open symb
anel) with time (mean, 95% confidence interval) for patients randomized
he number of patients seen at each time point. Time represents the durati
rial) to patient follow-up visit at which tonometry measurement was ma
ermission from the CAFE Investigators (26). AUC  area under the culack (35%). No significant difference was found between creatment groups for the primary coronary heart disease
CHD) outcome in either racial subgroup (31). For lisino-
ril versus chlorthalidone, systolic BP was lowered more
ffectively with the diuretic, and this coincided with more
ffective stroke prevention in black patients (relative risk
RR] 1.40 [95% confidence interval 1.17 to 1.68]) with the
iuretic. The difference in stroke rate is likely to be caused
y the differences in BP control. There was less difference in
P control between treatments in nonblack patients, and no
ignificant difference in stroke rate (Table 1).
The comparison of amlodipine with chlorthalidone
howed that despite slightly more effective control of systolic
P throughout the study with the diuretic, there were no
ifferences in the primary and major secondary end points in
lack patients and nonblack patients (31). The exception is
he higher rate of heart failure in black patients and
onblack patients with either lisinopril or amlodipine when
ystolic blood pressure (SBP) (top panel) and pulse pressure (PP) (lower
nolol- versus amlodipine-based therapy. Numbers below abscissa represent
m randomization into ASCOT (Anglo-Scandinavian Cardiac Outcomes
the CAFE (Conduit Artery Function Evaluation) study. Reprinted withols) s
to ate
on froompared with the diuretic. This is perplexing for two
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October 17, 2006:1698–711 The Year in Hypertensioneasons: 1) The rates of heart failure are much higher in the
rst year, rather than in later years. This suggests that a
ikely cause was the withdrawal of previous diuretic therapy
efore randomization to lisinopril or amlodipine, unmask-
ng fluid retention previously controlled by diuretic therapy.
) The mortality in black patients and nonblack patients was
ot higher with amlodipine or lisinopril despite the reported
igh rates of incident heart failure. It is also worth noting
hat the rates of incident diabetes were highest in black
atients and nonblack patients with the diuretic therapy.
The main conclusions to be drawn from this important
eport are: 1) achieved BP is a powerful determinant of
utcome for black patients and nonblack patients, especially
or stroke, and 2) a thiazide-type diuretic or calcium channel
locker (CCB) will deliver the most effective initial BP
ontrol in black patients.
LLHAT outcomes in people with diabetes. The ALL-
AT investigators have also reported a prespecified sub-
roup analysis of people with type 2 diabetes (n  13,101)
r normoglycemia (17,012) at baseline (32). This is by far
he largest study of the treatment of hypertension in people
ith diabetes.
When comparing treatment arms, there was no signifi-
ant difference in relative risk for the primary outcome of
atal CHD or non-fatal myocardial infarction in people with
r without diabetes at baseline. These findings are impor-
ant because: 1) ALLHAT does not support the superiority
f angiotensin-converting enzyme (ACE) inhibition for the
revention of CHD in people with diabetes; 2) ALLHAT
oes not support the ill-founded concerns about the use of
CBs for people with diabetes generated in previous retro-
pective case-control studies, some meta-analyses, and
uch smaller prospective studies (34–37); 3) ALLHAT
rovides confirmation that thiazide-type diuretics are very
ffective and often an essential component of hypertension
reatment in people with type 2 diabetes.
These findings support the conclusions of a recent meta-
nalysis of patients with diabetes and hypertension random-
zed into major clinical outcome trials (38). This meta-
nalysis also analyzed the outcome in those with “more
able 1. ALLHAT (Antihypertensive and Lipid-Lowering Treat
nd Non-Blacks by Antihypertensive Treatment Group versus Ch
Outcome
Black
Amlodipine L
HD 0.99 (0.82–1.19) 1.07
ortality 0.97 (0.85–1.10) 1.07
troke 0.91 (0.72–1.15) 1.36
ombined CVD 1.03 (0.93–1.15) 1.17
eart failure*
First year 2.85 (1.75–4.66) 2.47
Beyond first year 1.23 (0.99–1.52) 1.13
The proportional hazards assumption was violated for the heart failure outcome. Fr
CHD  coronary heart disease; CI  confidence interval; CVD  cardiovasculaersus less intensive” (BP 5/3 mm Hg) BP lowering in aeople with or without diabetes at baseline. There was clear
enefit, reducing the risk of major cardiovascular events and
otal mortality, with the more intensive BP-lowering strat-
gy in people with diabetes. The benefit of this strategy was
ess clear for those without diabetes at baseline. These
ndings provide retrospective support for the more intensive
P-lowering strategy advocated for people with diabetes in
reatment guidelines.
LLHAT renal outcomes in high-risk hypertensive pa-
ients. This post-hoc analysis of the ALLHAT database
xamined whether treatment with either a CCB or an ACE
nhibitor influenced the likelihood of developing end-stage
enal disease (ESRD) or a reduction in glomerular filtration
ate (GFR) of at least 50%, when compared with treatment
ith a thiazide-type diuretic, over a mean follow-up of 4.9
ears (33). Patients were stratified according to their base-
ine GFR (estimated by the simplified Modification of Diet
n Renal Disease equation), into 3 categories: normal or
ncreased GFR (90 ml/min per 1.73 m2, n 8,126), mild
eduction in GFR (60 to 89 ml/min per 1.73 m2, n 
8,109), or moderate-severe reduction in GFR (60 ml/
in per 1.73 m2, n  5,662). In 448 participants ESRD
eveloped, and in 1,049 the composite end point developed,
efined as a 50% or greater decline in GFR or ESRD. There
as no difference in treatment effects for either end point for
atients taking amlodipine or lisinopril compared with
hose taking chlorthalidone across the 3 GFR subgroups,
ither for the total group or for participants with diabetes at
aseline.
These are important and intriguing findings. They chal-
enge the view that renin angiotensin aldosterone system
RAAS) blockade is especially renoprotective in people with
ifferent categories of renal disease. The findings cannot be
ismissed lightly because the number of patients in each
ategory of mild and moderate renal insufficiency in ALL-
AT exceeded the total number of similar patients in many
enal outcome studies. Moreover, the number of patients
ho reached ESRD in ALLHAT was greater than in any
revious renal trial. Furthermore, in previous studies exam-
ning renoprotection in which the benefits of RAAS block-
to Prevent Heart Attack Trial) Clinical Outcomes in Blacks
alidone After Time-Dependent Blood Pressure Adjustment
RR (95% CI)
Non-Black
pril Amlodipine Lisinopril
–1.28) 0.95 (0.85–1.08) 0.93 (0.83–1.05)
–1.21) 0.92 (0.83–1.02) 0.96 (0.87–1.06)
–1.68) 0.91 (0.76–1.10) 0.97 (0.81–1.17)
–1.29) 1.01 (0.94–1.08) 1.04 (0.97–1.12)
–4.10) 2.49 (1.68–3.68) 2.14 (1.43–3.20)
–1.41) 1.16 (1.00–1.35) 1.01 (0.87–1.19)
right Jr. et al. (31).
se; RR  relative risk.ment
lorth
isino
(0.90
(0.94
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The Year in Hypertension October 17, 2006:1698–711n-treatment BP favoring the RAAS blockade group. In
LLHAT, the converse was true. This supports the view
hat BP lowering is a key driver of renoprotection. Never-
heless, there are caveats. The ALLHAT did not measure
rinary albumin excretion, and it is conceivable that the
enoprotective benefits of RAAS blockade are more pro-
ounced in people with significant albuminuria. Also, the
LLHAT investigators concede that it was likely that
therosclerotic or ischemic kidney disease (i.e., tubulointer-
titial disease) accounted for much of the renal insufficiency
n their patients and that this type of renal injury may be less
menable to the protective effect of RAAS blockade (33).
he MOSES study. The MOSES (Morbidity and Mor-
ality After Stroke, Eprosartan Compared With Nitrendip-
ne for Secondary Prevention) study evaluated BP lowering
or secondary prevention in patients who had suffered a
omputed tomography– or magnetic resonance imaging–
ocumented cerebral event in the previous 24 months (39).
he study compared BP lowering with either an ARB-
ased (eprosartan), or CCB-based (nitrendipine) therapy.
lood pressure control was similar with both treatment
trategies. The primary end point of the MOSES study was
he composite of all-cause mortality and the number of
ardiovascular and cerebrovascular events, including all re-
urrent events. This was significantly reduced by eprosartan-
ased therapy (incidence density ratio 0.79, 95% confidence
nterval 0.66 to 0.96, p  0.014). It is unusual not to focus
he primary end point of an outcome trial on first event,
ather than also counting additional events in the same
atient. Nevertheless, when only first events were included
n the analysis, a similar trend of benefit for the ARB was
bserved. Further studies of optimal timing and treatment
trategies for BP lowering in the secondary prevention of
troke are needed.
TRIAL FIBRILLATION IN HYPERTENSION
ypertensive patients are at increased risk of developing
trial fibrillation and/or flutter (AF), and this further in-
reases their risk of cardiovascular morbidity and mortality
40–42). Recent studies have suggested that the choice of
P-lowering medication can influence the risk of develop-
ng AF in people with hypertension. In a post-hoc analysis
rom the LIFE (Losartan Intervention for End Point
eduction in Hypertension) study, 8,851 patients with
ypertension and electrocardiographic (ECG)-left ventric-
lar hypertrophy (LVH) but without AF by ECG or history
ere followed up for almost 5 years, during which they were
reated with either losartan-based or atenolol-based BP-
owering therapy (43). New AF occurred in 150 patients
andomized to losartan versus in 221 randomized to ateno-
ol (6.8 vs. 10.1 per 1,000 person-years, p  0.001), a
elative risk reduction of 33%.
The 4 main factors predicting the risk of developing AF
n the LIFE study in order of effect size were: 1) age (each
ear of age associated with a 9% higher rate of new-onset (F), 2) male gender (56% increase in risk compared with
omen), 3) systolic BP (6% increase per 10 mm Hg), and 4)
he magnitude of ECG-LVH by Cornell product (4%
ncrease per 100 mV · ms) (Table 2). In addition, random-
zation to losartan rather than to atenolol was associated
ith a 33% lower rate of new-onset AF independent of
ther risk factors (p 0.001). Furthermore, patients receiv-
ng losartan-based therapy tended to stay in sinus rhythm
onger.
Another important finding in a companion report from
he LIFE study was that the choice of BP-lowering therapy
lso influenced the risk of cardiovascular events in people
ith hypertension, ECG-LVH, and a history of AF (44). In
atients with a history of AF, when compared with those
ithout such a history, there were substantial increases in
he risk of total and cardiovascular mortality, stroke, heart
ailure, and sudden cardiac death (Table 3A). This risk in
eople with AF was significantly reduced in those treated
ith losartan-based therapy compared with atenolol-based
herapy (Table 3B).
The findings of a reduced risk of developing AF in people
ith hypertension treated with an ARB are supported by
nother recent study by Fogari et al. (45) that compared
osartan with amlodipine therapy in people with hyperten-
ion but with a prior history of AF. The objective was to
etermine the influence of BP-lowering therapy on the risk
f recurrent AF. In a double-blind study, the 222 patients
ere all in sinus rhythm at the time of randomization but
ad at least 2 ECG-documented episodes of AF in the
revious 6 months and were currently treated with amioda-
one to suppress further AF. Monthly 24-h ECGs were
erformed over a median follow-up of 299 days. Despite
imilar clinic BP control, at least 1 ECG-documented AF
pisode occurred less frequently in those receiving losartan-
ased therapy (13%) compared with amlodipine therapy
able 2. Univariate Predictors of the Onset of Atrial Fibrillation
n People With Hypertension and ECG-LVH From the LIFE
tudy
Variable
Hazard Ratio
(95% CI) p Value
ge (yrs) 1.09 (1.07–1.10) 0.001
ale gender 1.3 (1.06–1.60) 0.011
ystolic blood pressure (mm Hg) 1.02 (1.01–1.02) 0.001
iastolic blood pressure (mm Hg) 0.99 (0.98–1.00) 0.046
ornell voltage-duration (mV · ms/100) 1.013 (1.004–1.022) 0.006
okolow-Lyon voltage (mV) 1.01 (0.997–1.02) 0.170
ramingham risk score (%) 1.02 (1.01–1.03) 0.001
oronary disease (yes/no) 1.28 (0.99–1.67) 0.062
otal cholesterol (mmol/l) 0.89 (0.80–0.98) 0.014
otassium (mmol/l) 0.78 (0.58–1.04) 0.091
og UACR (mg/mmol) 1.44 (1.23–1.67) 0.001
reatment with losartan 0.67 (0.54–0.82) 0.001
eart rate, body mass index, diabetes, cerebral and peripheral vascular disease,
igh-density lipoprotein cholesterol, plasma glucose, and creatinine were not signif-
cant predictors (p  0.20). From Wachtell et al. (43).
CI  confidence interval; ECG-LVH  electrocardiographic-left ventricular
ypertrophy; UACR  urine albumin/creatinine ratio.39%), p  0.01.
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October 17, 2006:1698–711 The Year in HypertensionPrevious studies have suggested that blockade of the
AAS with either ACE inhibition or an ARB can reduce
he risk of developing AF (46–48), but these studies usually
ompared active drug with placebo, thus it was unclear
hether the reduction in incident AF was related to BP
owering or to a specific drug effect. These new data from
he studies cited earlier imply a drug treatment effect
ecause there was no difference in BP reduction between the
reatment arms. Moreover, the findings from the LIFE
tudy will come as a surprise to many who have considered
eta-blockade a preferred therapy for preventing AF as well
s the preferred treatment for rate control in established AF
49).
It is tempting to speculate on the mechanisms underpin-
ing these observations. At the cellular level, studies in
nimals have suggested the potential for blockade of the
ction of angiotensin II to prolong the action potential and
revent the acute electrical remodeling response to short-
able 3. End Points in People: With and Without a History of A
eople With AF, From the LIFE Study (Panel B)
Pa
End Points
Atrial Fibrillation
(n  342)
Nonat
Fibrilla
(n  8,
Rate† n (%) Rate† n
rimary composite end point 70.0 103 30.1 23.5 99
omponents
Cardiovascular mortality 36.1 58 17.0 8.7 38
Stroke 35.8 56 16.4 11.2 48
Myocardial infarction 11.3 19 5.6 8.4 36
ther prespecified end points
Total mortality 50.2 79 23.1 17.1 73
Hospitalization for
Angina pectoria 7.1 12 3.5 5.6 24
Heart failure 24.1 41 12.0 6.1 26
Revascularization 15.6 26 7.6 4.7 20
Sudden cardiac death‡ 15.5 26 7.6 3.7 16
P
End Points
Losartan
(n  157)
Ateno
(n  1
Rate† n (%) Rate† n
rimary composite end point 50.3 36 22.9 88.8 67
omponents
Cardiovascular mortality 26.2 20 12.7 45.2 38
Stroke 24.1 18 11.5 46.5 38
Myocardial infarction 14.2 11 7.0 8.9 8
ther prespecified end points
Total mortality 40.1 30 19.1 59.4 49
Hospitalization for
Angina pectoris 7.7 6 3.8 6.5 6
Heart failure 19.1 15 9.6 30.1 26
Revascularization 14.2 11 7.0 16.9 15
Sudden cardiac death‡ 11.4 9 5.7 19.3 17
For degree of left ventricular hypertrophy, Framingham risk score, and treatment allo
rrest, cardiac death within 24 h. From Wachtell et al. (44).
CI  confidence interval.erm rapid atrial pacing (50,51). Others have shown no rffect on electrical remodeling to more chronic atrial pacing
nd no effect of angiotensin II infusions on electrical
hysiology in humans (52). Other possibilities relate to the
eneficial effects of blockade of RAAS, or more specifically
he angiotensin II receptor, on atrial fibrosis (53), LVH
egression, remodeling, and left atrial size (54,55). What-
ver the mechanism, these findings should prompt formal
tudies of the role of RAAS blockade (ACE inhibition,
RB or renin inhibition) in the prevention of new and
ecurrent AF in people with and without hypertension and
n the role of routine RAAS blockade in the prevention of
ardiovascular events in people with established refractory
F.
ETA-BLOCKERS AND HYPERTENSION
ne of the most significant developments in the past year
as been a re-evaluation of the role of beta-blockers as a
anel A); and in Losartan- Versus Atenolol-Based Therapy in
Adjusted
Hazard Ratio*
p
Value
Unadjusted
Hazard Ratio
p
Value(%) 95% CI 95% CI
11.2 2.23 1.81–2.74 0.001 2.95 2.4–3.62 0.001
0.001
4.3 3.06 2.31–4.06 0.001 4.19 3.18–5.52 0.001
5.5 2.44 1.84–3.25 0.001 3.08 2.33–4.08 0.001
4.1 1.03 0.65–1.64 0.895 1.34 0.85–2.13 0.209
8.3 2.32 1.83–2.93 0.001 2.99 2.37–3.78 0.001
2.8 0.95 2.16–4.24 0.866 1.26 0.7–2.24 0.440
1.0 3.02 1.56–3.59 0.001 4.15 2.99–5.76 0.001
2.3 2.37 1.56–3.59 0.001 3.37 2.24–5.06 0.001
1.9 2.93 1.92–4.48 0.001 4.21 2.78–6.36 0.001
Adjusted Hazard
Ratio*
p
Value
Unadjusted
Hazard Ratio
p
Value(%) 95% CI 95% CI
36.2 0.58 0.39–0.88 0.009 0.58 0.39–0.87 0.009
20.5 0.58 0.33–0.99 0.048 0.58 0.33–0.99 0.045
20.5 0.55 0.31–0.97 0.039 0.55 0.31–0.97 0.038
4.3 1.49 0.60–3.72 0.392 1.63 0.65–4.04 0.296
26.5 0.67 0.43–1.06 0.090 0.67 0.42–1.05 0.079
3.2 1.18 0.38–3.69 0.778 0.65 0.34–1.22 0.182
14.1 0.66 0.35–1.25 0.206 1.14 0.37–3.53 0.824
8.1 0.82 0.38–1.79 0.615 0.83 0.38–1.82 0.647
9.2 0.57 0.25–1.29 0.179 0.59 0.26–1.33 0.204
. †Per 1,000 patient-years of follow-up; ‡Composite end point of resuscitated cardiacF (P
nel A
rial
tion
851)
3
0
5
7
5
7
5
5
4
anel B
lol
85)
cationoutine initial therapy for the treatment of hypertension.
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The Year in Hypertension October 17, 2006:1698–711his was prompted by a meta-analysis that included 13
andomized controlled trials (n  105,951) comparing
eta-blocker–based therapy for hypertension with other
ntihypertensive drugs and 7 studies (n  27,433) compar-
ng beta-blockers with placebo or no treatment (56). When
eta-blockers were compared with placebo or no treatment,
he relative risk of stroke was reduced by 19% (95%
onfidence interval 7% to 29%) (Fig. 6), which is about half
f that expected from an equivalent BP difference analyzed
rom previous hypertension trials (57). When compared
ith other BP-lowering therapies, the relative risk of stroke
as 16% higher for beta-blockers. There were no differences
igure 6. Clinical outcomes from a meta-analysis of hypertension trials co
eprinted with permission from Lindholm et al. (56). CI  confidence inn myocardial infarction or mortality (56). tThese data suggest that beta-blocker–based therapy is
uch less efficient at reducing the risk of stroke when
ompared with other treatment options for hypertension.
hy has the interpretation seemingly changed so suddenly?
he principal reason is that data on almost 55% of patients
ncluded in the meta-analysis, specifically examining a
eta-blocker as the initial therapy comparator, have been
cquired since 2002 (i.e., the LIFE study [58] and ASCOT
21]). In both of these studies, the alternative therapy was
nequivocally superior to the beta-blocker at reducing the
isk of stroke. In addition, analysis of the effectiveness
eta-blockers in prior studies was less clear-cut because
ing beta-blockers with other therapies for the treatment of hypertension.
l; RR  relative risk.mparherapy was often analyzed in combination with diuretics. A
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October 17, 2006:1698–711 The Year in Hypertensionurther reason has been a reluctance to concede that beta-
lockers may be less effective because of a popular but
ll-conceived perception that they are especially cardiopro-
ective when compared with other therapies. In addition to
uboptimal stroke prevention, LIFE and ASCOT also
howed a substantially increased risk of developing diabetes
ith beta-blocker–based therapy, 25% and 30% respec-
ively, when compared with other treatment options. A
ecent meta-analysis showed that when compared with
lternative treatments (often involving a thiazide), beta-
lockers, especially when combined with a thiazide, increase
he risk of developing diabetes by 20% (59). These data,
aken together with the observations that beta-blockers are
ess effective than alternatives at regressing cardiovascular
tructural changes and in preventing the development of AF
han anticipated (discussed earlier), are likely to condemn
eta-blockers when considering the preferred initial therapy
ptions for the routine treatment of hypertension in future
uidelines.
What are the potential mechanisms for less effective
troke prevention with beta-blockade? One possibility is
hat they are less effective at BP lowering than the
lternatives. This is supported by the early months of
SCOT and may be part of the explanation in older
atients (21). Nevertheless, it is not sufficient to explain
SCOT or the results of other studies such as LIFE.
nother possibility highlighted by the CAFE study (see
arlier) is that beta-blocker– based therapy may be less
fficient at lowering central aortic BP, despite similar
ffects on brachial BP (26). Another consideration is that
he adverse effects of beta-blocker therapy on the meta-
olic milieu, notably increased triglycerides, reduced
DL cholesterol, and impaired glycemic control, may all
onspire to reduce their effectiveness at optimally reduc-
ng cardiovascular disease risk.
There are a number of important caveats to the antici-
ated demise of beta-blockers for the routine initial treat-
ent of hypertension: 1) Most of the data for their role in
he treatment of hypertension have been acquired with
tenolol, the most popular beta-blocker used for the treat-
ent of hypertension worldwide. It is unclear whether the
utcomes would be similar with other beta-blockers, espe-
ially those with different pharmacologic properties. Never-
heless, in the absence of outcome data with other beta-
lockers in people with hypertension, it would be difficult to
upport their routine use as a preferred initial therapy for
ypertension. 2) There are specific indications for continued
se of beta-blockers in people with hypertension, irrespec-
ive of their BP effect, notably, in patients with symptomatic
ngina, chronic stable heart failure and after myocardial
nfarction. 3) Most of the trials of BP-lowering therapy have
een conducted in older patients, and it is unclear whether
he same concerns would apply to younger people with
ypertension, in whom their BP-lowering efficacy may on
ccasion exceed that of other classes of therapy. 4) There are
lso circumstances in which alternative treatments may be loorly tolerated or contraindicated, or ineffective at control-
ing BP, circumstances in which it would be perfectly
easonable to select a beta-blocker to lower BP, the benefits
f which exceed no treatment at all. This is a debate of great
mportance and one that will continue to generate much
nterest.
UMMARY AND REFLECTIONS
he past year has generated a wealth of new and
mportant data. Increased awareness of the early hyper-
ensive phenotype, its nonbenign nature, and the impor-
ance of considering earlier intervention with drug ther-
py is a milestone that should prompt new studies in this
rea. The new clinical trial data and ongoing analyses of
mportant subgroups of patients continue to illuminate
ur understanding of BP-lowering therapies and have
hallenged well-entrenched dogma. The data from
SCOT showing the powerful complementary benefits
f statin therapy in hypertensive patients at reducing
ardiovascular disease risk is impressive and should lead
o increased routine use of statins in people with hyper-
ension. Moreover, the data showing that subtle distur-
ances to lipid profiles exist in the early evolution of
ypertension suggests the need for a radical reappraisal of
urrent thinking about when treatment should begin and
hether early use of BP- and lipid-lowering drugs could
revent the onset of more severe, multi-drug–resistant
ypertension.
However, let us not lose sight of how little we know about
ow current BP therapies may or may not work. The CAFE
tudy and others have highlighted the importance of studies
f human vascular function that will be further enhanced by
he emergence of ever-improving imaging modalities. No
oubt, this will cause us to lament the lost tribes of
ardiovascular physiologists and will emphasize how studies
f human physiology and its response to modern drug
herapy need to be reinvigorated to better define how
xisting drugs work and how future novel therapies might
e developed.
Around the corner is the launch of a new class of
P-lowering drugs—the renin inhibitors, and the late-stage
valuation in treatment-resistant hypertension of drugs that
nhibit endothelin, new combinations of BP-lowering
rugs, further analyses from recent clinical outcome trials,
ontinuing debate about beta-blockers and the clinical
ignificance of drug-induced diabetes, and ultimately the
ssimilation of these new data into hypertension treatment
uidelines. Who said hypertension was sorted!
eprint requests and correspondence: Dr. Bryan Williams,
linical Sciences Building, Leicester Royal Infirmary, PO Box
5, Leicester, LE2 7LX, United Kingdom. E-mail: www.bw17@
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